Patient-Centricity at the Heart of Innovation

Tools4Patient was founded with the goal of developing innovative, sophisticated tools to optimize clinical trial design and data analysis, with the ultimate objective of providing safer and more efficacious treatments for patients. The essence of the company, as our name suggests, is driven by our continual focus on the individual patient. From the outset, our goal has been to first understand the unique characteristics of each individual patient and then to apply this knowledge to the development of technologies to improve clinical data interpretation. Tools4Patient’s patient-centric approach and our progress in characterizing individual patient response in clinical trials will be presented at the upcoming Patient Partnering in Clinical Development conference on 20 March 2019 in Berlin, Germany.

Why is maintaining a patient-centric focus critical when innovating predictive tools for clinical trials? Clearly, each patient who participates in a clinical trial has a unique response to the given treatment that is influenced by their individual personality, disease history, and life experiences. Understanding the impact of these factors on study results enables the biopharma industry to design better clinical trials and ultimately accelerate the launch of excellent therapies that will benefit all patients.

Combining this philosophy with advanced mathematical approaches like machine learning led to the launch of Placebell©™, Tools4Patient’s first proprietary tool that predicts each individual patient’s placebo response resulting in more accurate analysis of clinical trial data. This approach incorporates patient personality traits – like expectation and optimism – into our proprietary algorithms to calculate the individual placebo co-variate, which is used in the statistical analysis to reduce data variability. In all our efforts, we strive to derive maximum utility from clinical data generated in each trial by committing to more fully understand each patient as an individual.